Nanotechnologies to use bisphosphonates as potent anticancer agents: The effects of zoledronic acid encapsulated into liposomes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 955-964

  Marra, Monica ^a   Salzano, Giuseppina ^b   Leonetti, Carlo ^c   Tassone, Pierfrancesco ^d   Scarsella, Marco ^c   Zappavigna, Silvia ^a   Calimeri, Teresa ^d   Franco, Renato ^e   Liguori, Giuseppina ^e   Cigliana, Giovanni ^c   Ascani, Roberta ^c   La Rotonda, Maria Immacolata ^b   Abbruzzese, Alberto ^a   Tagliaferri, Pierosandro ^d   Caraglia, Michele ^a   De Rosa, Giuseppe ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Aminobisphosphonates; Multiple myeloma; Prostate cancer; Stealth liposomes; Tumor targeting; Zoledronic acid

Indexed keywords

AMINOBISPHOSPHONATES; MULTIPLE MYELOMA; PROSTATE CANCERS; STEALTH LIPOSOMES; TUMOR TARGETING; ZOLEDRONIC ACID;

BONE; CELL CULTURE; HISTOLOGY; LIPOSOMES; PHOSPHOLIPIDS; TUMORS;

DISEASES;

DOXORUBICIN; LIPOSOME; LIPOSOME ZOLEDRONIC ACID MACROGOL 20; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; MULTIPLE MYELOMA; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HUMANS; IMIDAZOLES; LIPOSOMES; MALE; MICE; MICE, NUDE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS;

ANIMALIA; MURINAE;

EID: 82255175215     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.03.004     Document Type: Article

References (48)

1. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
2. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G., Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997, 98:665-672.
3. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.
4. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82:1459-1468.
5. Lee M.V., Fong E.M., Singer F.R., Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001, 61:2602-2608.
6. Caraglia M., Budillon A., Tagliaferri P., Marra M., Abbruzzese A., Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005, 6:301-323.
7. Hancock J.F., Magee A.I., Childs J.E., Marshall C.J. All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57:1167-1177.
8. Aznar S., Lacal J.C. Rho signals to cell growth and apoptosis. Cancer Lett 2001, 165:1-10.
9. Caraglia M., Marra M., Leonetti C., Meo G., D'Alessandro A.M., Baldi A., et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007, 211:533-543.
10. Caraglia M., D'Alessandro A.M., Marra M., Giuberti G., Vitale G., Viscomi C., et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004, 23:6900-6913.
11. Haluska P., Dy G.K., Adjei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002, 38:1685-1700.
12. Tassone P., Forciniti S., Galea E., Morrone G., Turco M.C., Martinelli V., et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14:841-844.
13. Marra M., Abbruzzese A., Addeo R., Del Prete S., Tassone P., Tonini G., et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009, 9:791-800.
14. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Pöstlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
15. Caraglia M., Marra M., Naviglio S., Botti G., Addeo R., Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010, 11:141-154.
16. Miwa S., Mizokami A., Konaka H., Izumi K., Nohara T., Namiki M. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol 2009, 39:745-750.
17. van Rooijen N., van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002, 12:81-94.
18. Danenberg H.D., Golomb G., Groothuis A., Gao J., Epstein H., Swaminathan R.V., et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003, 108:2798-2804.
19. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:1620.
20. Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5:25-44.
21. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445-2451.
22. Cattel L., Ceruti M., Dosio F. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J Chemother 2004, 16(Suppl):94-97.
23. Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 1978, 75:4194-4198.
24. Stewart J.C.M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980, 104:10-14.
25. Tassone P., Goldmacher V.S., Neri P., Gozzini A., Shammas M.A., Whiteman K.R., et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004, 104:3688-3696.
26. Neri P., Kumar S., Fulciniti M.T., Vallet S., Chhetri S., Mukherjee S., et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007, 13:5903-5909.
27. Sommer K., Peters S.O., Robins I.H., Raap M., Wiedemann G.J., Remmert S., et al. A preclinical model for experimental chemotherapy of human head and neck cancer. Int J Oncol 2001, 18:1145-1149.
28. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143:401-409.
29. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:9629.
30. Tassone P., Tagliaferri P., Rossi M., Calimeri T., Bulotta A., Abbruzzese A., et al. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 2009, 9:854-870.
31. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157:427-435.
32. Senaratne S.G., Mansi J.L., Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002, 86:1479-1486.
33. Sewing L., Steinberg F., Schmidt H., Göke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008, 13:782-789.
34. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60:2949-2954.
35. Wood J., Bonjean K., Ruetz S., Bellahcène A., Devy L., Foidart J.M., Castronovo V., Green J.R., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
36. Croucher P.I., De Hendrik R., Perry M.J., Hijzen A., Shipman C.M., Lippitt J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003, 18:482-492.
37. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
38. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
39. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009, 9:824-833.
40. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., LoRusso P., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236.
41. Skerjanec A., Berenson J., Hsu C., Major P., Miller W.H., Ravera C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43:154-162.
42. Weiss H.M., Pfaar U., Schweitzer A., Wiegand H., Skerjanec A., Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008, 36:2043-2049.
43. van Rooijen N., Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010, 605:189-203.
44. Litzinger D.C., Buiting A.M., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994, 1190:99-107.
45. Zhang J.A., Pawelchak J. Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditions. Part 1: lipid hydrolysis. Eur J Pharm Biopharm 2000, 50:357-364.
46. Thompson K., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69:1624-1632.
47. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
48. Hwang C., Heath E.I. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010, 3:26-36.